AmerisourceBergen 2014 Annual Report Download - page 12

4
10
Specialty is the fastest growing
area of prescription drug sales in the
U.S. and across the world. The current
research and development pipeline
for new products is heavily weighted
towards specialty products, particularly
in oncology, as reported by the Center
for Supply Chain Research. At the same
time, changes in reimbursement models
and other evolutionary changes are
shifting sites of care between physician
offices, hospitals, retail and specialty
pharmacy, and alternate sites of care.
Discussions regarding specialty products
and services permeate nearly every
business relationship we have, and
these changes present opportunities
for the specialty providers we serve.
Community care providers are well
positioned to deliver value through
coordinating multiple services, managing
drug spend, and ultimately reducing
emergency room visits and inpatient
hospitalizations. Patients are well
served in a community setting,
both in terms of ease of access and
convenience as well as in the quality
of care. Community providers must
continue to adopt new approaches
to improve the total cost and quality
of care, and AmerisourceBergen is
uniquely positioned to help shape
those changes.
Specialty therapies are, however,
increasingly administered across all
sites of care, and AmerisourceBergen
Specialty Group (ABSG) is
exceptionally well positioned to serve
both community physician practices
as well as hospitals and health systems.
ABSG is the undisputed leader in
oncology product distribution in the U.S.,
the number one distributor of blood
derivatives, the leading distributor in
dialysis and most physician specialties,
and has tens of thousands of active
customers for vaccines, biologics, and
other injectables. In addition, we also